PARP Inhibitors in Cancer Therapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 June 2026 | Viewed by 20
Special Issue Editors
2. Department of Medicine, Harvard Medical School, Boston, MA 02215, USA
Interests: drug discovery; targeted protein degradation; chemical biology
Special Issue Information
Dear Colleagues,
Over the past decade, poly(ADP-ribose) polymerases (PARPs) have emerged as a new target in cancer therapy. PARP inhibitors act through synthetic lethality with mutations in DNA repair genes and were approved for the treatment of BRCA-mutated ovarian and breast cancer. This Special Issue aims to provide a comprehensive overview of the evolving role of PARP inhibitors in oncology, from mechanistic insights and biomarkers of response to resistance mechanisms and novel therapeutic combinations. As we deepen our understanding of DNA repair pathways and tumor heterogeneity, the potential for PARP inhibitors continues to expand—offering new hope for precision oncology and personalized medicine. This Special Issue welcomes reviews, as well as original research articles.
Dr. Jie Jiang
Dr. Fu Gui
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- PARP inhibitors
- cancer therapy
- DNA damage repair
- drug discovery
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
